🔬
01
Technical and Scientific Information
CJC-1295 WITHOUT DAC — GH / GHRH AXIS
CJC-1295 is described in the source document as a synthetic peptide intended to mimic growth hormone-releasing hormone (GHRH). The short-acting formulation, commonly identified as modified GRF (1-29), is investigated for its interaction with the physiological regulation of growth hormone (GH) secretion.
WHAT DOES “WITHOUT DAC” MEAN?
DAC refers to Drug Affinity Complex, a modification intended to prolong peptide exposure. CJC-1295 without DAC is described in the source as a shorter-acting formulation, also referred to as Mod GRF (1-29). The source associates its development with optimization of GHRH signaling along the hypothalamic-pituitary axis.
WHAT DOES CJC-1295 WITHOUT DAC DO?
The proposed mechanism involves binding to GHRH receptors in the anterior pituitary and stimulating endogenous GH release. The source describes this response as pulsatile and subject to physiological feedback regulation. It also claims that this process does not suppress endogenous production; that claim should not be accepted as established without clinical evidence.
MECHANISM OF ACTION
The hypothalamic-pituitary axis regulates GH secretion. Stimulation of pituitary GHRH receptors can influence pulsatile GH release and downstream hepatic insulin-like growth factor 1 (IGF-1) production. CJC-1295 is not growth hormone itself. The document characterizes receptor stimulation as more physiologically oriented than administering exogenous GH.
The claims concerning selectivity, feedback preservation, and safety require evaluation in the context of the specific compound and formulation studied.
🔬
02
Technical and Scientific Information
CJC-1295 WITHOUT DAC — PHYSIOLOGY / RESEARCH
PHYSIOLOGICAL FUNCTIONS DISCUSSED IN THE SOURCE
The document associates the GH–IGF-1 axis with protein synthesis, tissue repair, lipolysis, and skeletal-muscle recovery. It also refers to anti-aging, body recomposition, and recovery claims. These are areas of proposed investigation rather than demonstrated benefits of this particular product.
SETTINGS MENTIONED IN THE ORIGINAL DOCUMENT
The source discusses interest in fitness, bodybuilding, and longevity-oriented clinical settings.
RESEARCH FINDINGS DESCRIBED
The document lists increased GH release, sustained IGF-1 activity, a potentially favorable pharmacokinetic profile, and physiological stimulation of the GH regulatory system.
It additionally discusses aging, metabolic regulation, sarcopenia, body composition, tissue repair, skeletal muscle, bone, and possible interactions with growth hormone-releasing peptides (GHRPs), including ipamorelin.
CJC-1295 without DAC is described as a short-acting GHRH analogue designed to investigate physiological GH secretion and modulation of the GH–IGF-1 axis.
PROPOSED BENEFITS
The source claims faster muscle recovery, enhanced muscle-tissue repair, and reduced recovery time between workouts. Those claims do not establish clinically demonstrated efficacy in humans.
🔬
03
Technical and Scientific Information
CJC-1295 WITHOUT DAC — BENEFITS / PROTOCOL
ADDITIONAL EFFECTS CLAIMED BY THE SOURCE
The original document discusses progressive fat loss through lipolysis, greater utilization of fatty acids as an energy substrate, deeper sleep, collagen synthesis, skin and hair quality, increased baseline energy, and systemic recovery.
These statements describe proposed or promotional effects and should not be interpreted as verified therapeutic outcomes.
DOSING AND CYCLE INFORMATION IN THE ORIGINAL DOCUMENT
The source contains an indicative injection schedule expressed as 5–8 units per administration, one to three times daily. It mentions fasting conditions, an optional post-exercise schedule, cycles of approximately 12–16 weeks, five days of administration followed by two days off, and rest intervals of four to six weeks.
The document also discusses avoiding excessive receptor stimulation and reports possible local redness, mild fluid retention, transient warmth, and headache.
Further advice in the source concerns physiological dosing, avoiding sugar immediately beforehand, adequate sleep, hydration, limiting frequency, and adjusting dosing when combining peptides.
CRITICAL SCIENTIFIC NOTE
These schedules are included solely to preserve the content of the original document. “Units” does not define a peptide mass without a verified concentration. The source does not establish a validated safe or effective human dosing regimen.
The photograph supplied for this product identifies a CJC-1295 and ipamorelin combination. It must not be used to represent CJC-1295 alone.